Article Text

Download PDFPDF

  1. F. Veenstra1,
  2. J. Vriezekolk1,
  3. H. J. Schers2,
  4. N. Van Herwaarden1,3,
  5. B. Van den Bemt4,5,
  6. M. Flendrie1
  1. 1Sint Maartenskliniek, Rheumatology, Ubbergen, Netherlands
  2. 2Radboud University Medical Center, Primary and Community Care, Nijmegen, Netherlands
  3. 3Radboud University Medical Center, Rheumatology, Nijmegen, Netherlands
  4. 4Sint Maartenskliniek, Rheumatology & Pharmacy, Ubbergen, Netherlands
  5. 5Radboud University Medical Center, Pharmacy, Nijmegen, Netherlands


Background: Uric acid lowering therapy (ULT) can be effective in gout if taken correctly (1), but non-adherence is a known problem (2). Although patients’ adherence barriers regarding ULT, such as lack of knowledge on disease and therapy, and beliefs, have been widely studied (3), less is known physicians’ beliefs.

Objectives: To investigate the physicians’ beliefs on ULT treatment in both primary and secondary care in the Netherlands.

Methods: Cross-sectional study among all rheumatologists of the Sint Maartenskliniek and to all General Practitioners (GPs) of 17 practices, participating in the practice-based research network Family Medicine Network Nijmegen, Netherlands. All participants filled out the beliefs about medication questionnaire (BMQ), adjusted for physicians; in addition data were collected on physician characteristics including working experience in total and gout consultations. The BMQ consists of two parts, a specific part with 10 questions about beliefs on necessity (N=5) and concerns (N=5) regarding ULT and a general part with 8 questions about beliefs on harms (N=4) and overuse (N=4) regarding medication in general. Each question is scored on a Likert-scale from 1-5, a higher score corresponds to higher beliefs on that category. Sum scores for all four categories were calculated. With the total scores on the specific BMQ including necessity and concerns beliefs, physicians were classified in four different categories (Table 1)(4).

Results: In total 112 physicians received the questionnaire, 28 of 37 rheumatologists (76%) and 45 of 75 GPs (60%) responded. Rheumatologists had less years of experience than GPs (median 8.5 years (IQR 3 – 14) versus (vs) 13 years (IQR 8-20)) and less hours of patient contact per week (15 hours (IQR 8.5 – 20) vs 24 hours (IQR 20 – 30)). Rheumatologists reported more consultations for gout per week than GPs: median 4 (IQR 1 – 6.6) vs 1 (IQR 0.2– 1).

Rheumatologists scored higher on the BMQ necessity scale, 17.5 (95% CI 16.6 – 18.5) compared to GPs 16.1 (95% CI 15.1 – 17.1). GPs scored higher on BMQ concern scale, 12.1 (95% CI 11.4 – 12.7) compared to rheumatologists, 10.4 (95% CI 9.7 – 11.2). On medication in general, GPs scored higher on both overuse and harms scales compared to rheumatologists, 11.3 (95% CI 10.7 – 12) versus 9.9 (95% CI 9 – 10.7)and 8.3 (95% CI 7.9 – 8.7) vs 7.1 (95% CI 6.5 – 7.7), respectively. Table 1 shows classification according to the BMQ specific for both groups.

Table 1.

Classification based on the adapted BMQ

Conclusion: For the majority of rheumatologist the necessity beliefs outweighs concern beliefs towards the use of ULT outweighs concern beliefs. GPs show a more heterogenic profile, including acceptant, indifferent and ambivalent beliefs towards ULT use. GPs also show higher harm and overuse concerns regarding medication in general. Next step is to investigate possible associations with actual ULT use and disease outcome.

References: [1]Doherty M, et al. Lancet (London, England). 2018;392(10156):1403-12.

[2]Reach G. Joint, bone, spine: revue du rhumatisme. 2011;78(5):456-9.

[3]Harrold LR et al. Chronic illness. 2010;6(4):263-71.

[4]Toelichting BMQ. [updated 2011-12-10; cited 2021-01-28] Available trough:

Acknowledgements: This study is sponsored by Grünenthal

Disclosure of Interests: Frouwke Veenstra: None declared., Johanna Vriezekolk: None declared., Henk J Schers: None declared., Noortje van Herwaarden: None declared., Bart van den Bemt Speakers bureau: Pfizer, AbbVie, UCB, Biogen and Sandoz, Consultant of: Delivered consultancy work for UCB, Novartis and Pfizer, Grant/research support from: UCB, Pfizer and Abbvie, Marcel Flendrie Consultant of: M. Flendrie has received consultancy fees from Menarini and Grunenthal., Grant/research support from: M. Flendrie has received grants from Menarini and Grunenthal.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.